Thus, the PTEN/MTOR pathway could represent a therapeutic target in at least some of these cancers that could be shared by both ChRCC and CCRCC tumors, though one important caveat here is that even the presence of the same gene mutations may have differing effects dependent upon the cellular background. Here, MTOR is linked to nonpapillary renal cell carcinoma.